Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
European regulator amends some Gilead hep C patent claims
I-MAK, Indian Health Advocates Appeal Patent Office Reversal on Gilead’s Hepatitis C Drug
China Declined The Patent Application Of Gilead Sciences, Inc.’s Sovaldi Prodrug
China rejects patent linked to Gilead hepatitis C drug
Gilead Patent for its Sovaldi Hep C Drug is Rejected by Chinese Authorities
Activists Challenge Gilead’s Patents on Costly Hepatitis C Drug Sovaldi
Patent for hepatitis C treatment would cut access for millions, groups say
High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents
Gilead denied patent for hepatitis C drug sofosbuvir in India
Gilead denied patent for hepatitis C drug sofosbuvir in India